Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000220650 | SCV000270774 | likely benign | not specified | 2016-01-19 | criteria provided, single submitter | clinical testing | c.1224+15G>A in Intron 10 of PTPN11: This variant is not expected to have clinic al significance because a change at this position does not diverge from the spli ce consensus sequence and is therefore unlikely to impact splicing. Furthermore, aberrant splicing is not a known disease mechanism for Noonan syndrome. This va riant has been identified in 5/66706 European chromosomes by the Exome Aggregati on Consortium (ExAC, http://exac.broadinstitute.org/; dbSNP rs373271861). |
Gene |
RCV000220650 | SCV000514321 | likely benign | not specified | 2015-11-03 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Centre for Mendelian Genomics, |
RCV001197715 | SCV001368494 | benign | LEOPARD syndrome 1 | 2018-11-07 | criteria provided, single submitter | clinical testing | This variant was classified as: Benign. The following ACMG criteria were applied in classifying this variant: BS1,BS2,A. |
Labcorp Genetics |
RCV002057140 | SCV002388365 | likely benign | RASopathy | 2025-01-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002500700 | SCV002808971 | likely benign | Noonan syndrome 1; Juvenile myelomonocytic leukemia; Metachondromatosis; LEOPARD syndrome 1 | 2022-05-16 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000220650 | SCV005883622 | likely benign | not specified | 2024-12-12 | criteria provided, single submitter | clinical testing |